Paget’s disease does not always cause any symptoms and not everyone needs treatment. The main reason for treatment is if the affected bones are painful. If the pain is directly from Paget’s disease, it often improves with treatment. Pain, however, can arise from complications.
Bisphosphonates are drugs which work by inhibiting the bone remodelling process. These drugs reduce abnormal bone destruction by the osteoclasts, thereby restoring a more normal remodelling process.
For those who require treatment, the current first-line bisphosphonate, due to its potency and prolonged duration of action, is zoledronic acid. It is the bisphosphonate most likely to relieve pain from active Paget’s disease.
The main treatment goal is to control bone pain. The clinical benefit of giving bisphosphonates to patients who have a raised level of alkaline phosphatase in their blood, but do not have symptoms, is unknown.
Scroll down to see the individual tabs below for more information about treatment.
A clinical Guideline, for the diagnosis and management of Paget’s Disease of Bone in adults, was commissioned by the Paget's Association. The full Guideline was published in the Journal of Bone and Mineral Research. It has been endorsed by the European Calcified Tissues Society, the International Osteoporosis Foundation, the American Society of Bone and Mineral Research, the Bone Research Society (UK), and the British Geriatric Society.
You can read the clinical Guideline by following this link.
Facts Booklet. The Paget's Association updated its booklet, 'Paget's - The Facts', in line with the Guideline. This is available to download from the members' area of this website and also by contacting the Paget's Association.
Details regarding membership and its benefits can be found by following this link.